BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. HOOD
10. IBM

Go back to BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date

BioMarin Pharma (BMRN) Tops Q2 EPS by 31c, Offers Guidance

July 31, 2023 4:05 PM EDT

BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $0.54, $0.31 better than the analyst estimate of $0.23. Revenue for the quarter came in at $595.3 million versus the consensus estimate of $595.22 million.

GUIDANCE:

BioMarin Pharma sees FY2023 EPS of $1.80-$2.05, versus the consensus of... More